

Oxular announces 2nd UK Patent issued related to its proprietary Ocular Drug Delivery Device

02 January 2019 – Oxular Limited, the Oxford-based retinal therapeutics company, today announced the UK Intellectual Property Office granted GB-B-2543645 in a patent titled “Ophthalmic injection device.”

GB-B-2543645 provides a device for controlled delivery of an injection material to tissue spaces of an eye that are not normally open, such as the subconjunctival space, the suprachoroidal space and the subretinal space.

The invention also provides a device for controlled sub-retinal injection through a standard sclerostomy port used in retinal surgery. The cannula is placed into the sub-retinal space and the injection material is released by fingertip actuation while the device is held in a natural hand position. The rate of injection is controlled by the degree of actuation of the valve mechanism to allow the surgeon to create a desired bleb geometry in the region of retina to be treated.

We strongly believe this ocular drug delivery technology enables Oxular’s unique treatment approach which aims to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The drug delivery device is paired with companion cell or gene therapies to form a complete system which is engineered to enable more targeted and controlled delivery.

Enquiries

Ben Atwell

Tel: +44 (0) 2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications (www.oxular.com).